Cibeira M Teresa, Rozman María, Segarra Marta, Lozano Esther, Rosiñol Laura, Cid Maria C, Filella Xavier, Bladé Joan
Hematology Department, Institute of Hematology and Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic, University of Barcelona, Villarroel 170, Barcelona 08036, Spain.
Cytokine. 2008 Mar;41(3):244-53. doi: 10.1016/j.cyto.2007.11.017. Epub 2008 Jan 4.
An increased bone marrow (BM) angiogenesis is associated with poor outcome in multiple myeloma (MM).
Angiogenesis study in MM treated with novel antimyeloma agents: thalidomide, lenalidomide, bortezomib, and with dexamethasone.
Forty-four patients with MM (14 newly diagnosed, 30 refractory/relapsed) were treated with novel agents at our institution. A BM biopsy was obtained before the initiation of therapy in 19. Angiogenesis was assessed by microvessel density (MVD) estimation in BM biopsies stained with the monoclonal anti-CD34 antibody, and by serum levels of angiogenic factors (VEGF, bFGF, and HGF) and cytokines (IL-6 and TNF-alpha).
A positive correlation was found between BM plasma cell involvement and MVD estimation (p=0.01). However, MVD was not significantly correlated with either disease phase (p=0.065) or response to therapy (p=0.79). Neither baseline serum levels of angiogenic cytokines correlated to response to treatment. No significant correlation was found between BM MVD and serum levels of angiogenic cytokines. Serum levels of angiogenic cytokines before and after therapy showed a significant increase of bFGF (p=0.008).
There is no relationship between MVD estimation and baseline serum levels of angiogenic cytokines, neither between each of them and response to therapy.
骨髓血管生成增加与多发性骨髓瘤（MM）的不良预后相关。
对接受新型抗骨髓瘤药物（沙利度胺、来那度胺、硼替佐米）及地塞米松治疗的MM患者进行血管生成研究。
44例MM患者（14例新诊断，30例难治/复发）在我院接受新型药物治疗。19例患者在治疗开始前进行了骨髓活检。通过用单克隆抗CD34抗体染色的骨髓活检组织中的微血管密度（MVD）评估以及血管生成因子（VEGF、bFGF和HGF）和细胞因子（IL-6和TNF-α）的血清水平来评估血管生成。
骨髓浆细胞浸润与MVD评估之间存在正相关（p=0.01）。然而，MVD与疾病分期（p=0.065）或治疗反应（p=0.79）均无显著相关性。血管生成细胞因子的基线血清水平与治疗反应均无相关性。骨髓MVD与血管生成细胞因子的血清水平之间未发现显著相关性。治疗前后血管生成细胞因子的血清水平显示bFGF显著升高（p=0.008）。
MVD评估与血管生成细胞因子的基线血清水平之间、它们各自与治疗反应之间均无关联。
